Innovent Biologics (äæ”č¾¾ēē©) IPO:Ā Limited Upside Despite Strong Cornerstones (Part 3)
Innovent BiologicsĀ launched theĀ institutional book building today and intends to raise USD 377 to USD 423 million, with an implied market...
522 Views
Innovent Biologics IPO Valuation: Surprisingly Grounded in Reality
Innovent Biologics Inc (1641475D HK) launched its Hong Kong IPO today. The mid-point of Innovent's IPO price range of HK$12.50-14.00 per share...
859 Views
Innovent Biologics (äæ”č¾¾ēē©) IPO:Ā Pricing the PD-1 and Biosimilars Competition (Part 2)
Innovent Biologics, a leading biologics company in China, is raising up to USDĀ 500 million to list in Hong Kong. In our previous insight (link...
739 Views
Last Week in GER Research: Tencent Music Vs. Spotify, Ganfeng Lithium, Meituan, Weidai, and Innovent
Below is a recap of the key IPO research produced by the Global Equity Research team. This week we highlight why we think Tencent Music...
517 Views
Innovent Biologics IPO Preview: Limited Upside on China's PD-1 Drug Market Compared to BeiGene
Innovent Biologics Inc (1641475D HK)Ā is the fourth pre-profit biotech firm to IPO in Hong Kong since Ascletis Pharma Inc (1672 HK), BeiGene Ltd...
851 Views